Aptose Biosciences Inc (APS) - Net Assets
Based on the latest financial reports, Aptose Biosciences Inc (APS) has net assets worth CA$-19.45 Million CAD (≈ $-14.07 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$6.34 Million ≈ $4.59 Million USD) and total liabilities (CA$25.79 Million ≈ $18.66 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check APS financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$-19.45 Million |
| % of Total Assets | -306.73% |
| Annual Growth Rate | N/A |
| 5-Year Change | -103.82% |
| 10-Year Change | -133.28% |
| Growth Volatility | 798.58 |
Aptose Biosciences Inc - Net Assets Trend (1996–2024)
This chart illustrates how Aptose Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Also explore APS current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Aptose Biosciences Inc (1996–2024)
The table below shows the annual net assets of Aptose Biosciences Inc from 1996 to 2024. For live valuation and market cap data, see APS market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CA$-4.54 Million ≈ $-3.29 Million |
-56.60% |
| 2023-12-31 | CA$-2.90 Million ≈ $-2.10 Million |
-107.69% |
| 2022-12-31 | CA$37.74 Million ≈ $27.30 Million |
-49.16% |
| 2021-12-31 | CA$74.24 Million ≈ $53.70 Million |
-37.57% |
| 2020-12-31 | CA$118.92 Million ≈ $86.02 Million |
+26.60% |
| 2019-12-31 | CA$93.93 Million ≈ $67.94 Million |
+567.04% |
| 2018-12-31 | CA$14.08 Million ≈ $10.19 Million |
+38.02% |
| 2017-12-31 | CA$10.20 Million ≈ $7.38 Million |
+39.22% |
| 2016-12-31 | CA$7.33 Million ≈ $5.30 Million |
-46.32% |
| 2015-12-31 | CA$13.65 Million ≈ $9.87 Million |
-45.99% |
| 2014-12-31 | CA$25.28 Million ≈ $18.28 Million |
+3435.73% |
| 2013-12-31 | CA$-757.75K ≈ $-548.15K |
+61.23% |
| 2012-12-31 | CA$-1.95 Million ≈ $-1.41 Million |
-898.88% |
| 2011-12-31 | CA$244.66K ≈ $176.99K |
+147.63% |
| 2010-12-31 | CA$-513.68K ≈ $-371.59K |
+93.30% |
| 2009-12-31 | CA$-7.66 Million ≈ $-5.54 Million |
-97.76% |
| 2008-12-31 | CA$-3.87 Million ≈ $-2.80 Million |
-644.75% |
| 2007-12-31 | CA$711.16K ≈ $514.45K |
+130.64% |
| 2006-12-31 | CA$-2.32 Million ≈ $-1.68 Million |
-121.96% |
| 2005-12-31 | CA$10.57 Million ≈ $7.65 Million |
0.00% |
| 2004-12-31 | CA$10.57 Million ≈ $7.65 Million |
-49.64% |
| 2003-12-31 | CA$20.99 Million ≈ $15.19 Million |
-27.33% |
| 2002-12-31 | CA$28.89 Million ≈ $20.90 Million |
0.00% |
| 2001-12-31 | CA$28.89 Million ≈ $20.90 Million |
-20.61% |
| 2000-12-31 | CA$36.38 Million ≈ $26.32 Million |
-20.71% |
| 1999-12-31 | CA$45.89 Million ≈ $33.19 Million |
+3461.06% |
| 1998-12-31 | CA$1.29 Million ≈ $932.14K |
-60.90% |
| 1997-12-31 | CA$3.30 Million ≈ $2.38 Million |
-52.19% |
| 1996-12-31 | CA$6.89 Million ≈ $4.99 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Aptose Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 52050552852.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CA$457.40 Million | % |
| Other Comprehensive Income | CA$-4.32 Million | % |
| Other Components | CA$83.34 Million | % |
| Total Equity | CA$-4.54 Million | 100.00% |
Aptose Biosciences Inc Competitors by Market Cap
The table below lists competitors of Aptose Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
zSpace, Inc. Common stock
NASDAQ:ZSPC
|
$4.36 Million |
|
Nichols
LSE:NICL
|
$4.36 Million |
|
Tartana Minerals Ltd
AU:TAT
|
$4.36 Million |
|
Yunji Inc
NASDAQ:YJ
|
$4.36 Million |
|
Simble Solutions Ltd
AU:SIS
|
$4.35 Million |
|
Foresight Solar Fund Ltd
LSE:FSFL
|
$4.35 Million |
|
Terregra Asia Energy PT
JK:TGRA
|
$4.35 Million |
|
Gratomic Inc
V:GRAT
|
$4.35 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aptose Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -2,901,000 to -4,543,000, a change of -1,642,000.
- Net loss of 25,430,000 reduced equity.
- Share repurchases of 26,000 reduced equity.
- New share issuances of 23,407,000 increased equity.
- Other factors increased equity by 407,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-25.43 Million | -559.76% |
| Share Repurchases | CA$26.00K | -0.57% |
| Share Issuances | CA$23.41 Million | +515.23% |
| Other Changes | CA$407.00K | +8.96% |
| Total Change | CA$- | % |
Book Value vs Market Value Analysis
This analysis compares Aptose Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | CA$1240.87 | CA$2.36 | x |
| 1997-12-31 | CA$492.21 | CA$2.36 | x |
| 1998-12-31 | CA$183.82 | CA$2.36 | x |
| 1999-12-31 | CA$2877.30 | CA$2.36 | x |
| 2000-12-31 | CA$1395.71 | CA$2.36 | x |
| 2001-12-31 | CA$1087.19 | CA$2.36 | x |
| 2002-12-31 | CA$1087.19 | CA$2.36 | x |
| 2003-12-31 | CA$660.49 | CA$2.36 | x |
| 2004-12-31 | CA$331.68 | CA$2.36 | x |
| 2005-12-31 | CA$331.68 | CA$2.36 | x |
| 2006-12-31 | CA$-72.23 | CA$2.36 | x |
| 2007-12-31 | CA$18.75 | CA$2.36 | x |
| 2008-12-31 | CA$-97.27 | CA$2.36 | x |
| 2009-12-31 | CA$-167.45 | CA$2.36 | x |
| 2010-12-31 | CA$-9.86 | CA$2.36 | x |
| 2011-12-31 | CA$11.83 | CA$2.36 | x |
| 2012-12-31 | CA$-16.77 | CA$2.36 | x |
| 2013-12-31 | CA$-3.23 | CA$2.36 | x |
| 2014-12-31 | CA$32.67 | CA$2.36 | x |
| 2015-12-31 | CA$17.20 | CA$2.36 | x |
| 2016-12-31 | CA$8.63 | CA$2.36 | x |
| 2017-12-31 | CA$6.86 | CA$2.36 | x |
| 2018-12-31 | CA$6.33 | CA$2.36 | x |
| 2019-12-31 | CA$28.09 | CA$2.36 | x |
| 2020-12-31 | CA$40.15 | CA$2.36 | x |
| 2021-12-31 | CA$16.30 | CA$2.36 | x |
| 2022-12-31 | CA$6.14 | CA$2.36 | x |
| 2023-12-31 | CA$-0.43 | CA$2.36 | x |
| 2024-12-31 | CA$-0.02 | CA$2.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aptose Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-125.95%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -50.53% | -4800.03% | 0.01x | 1.12x | CA$-4.17 Million |
| 1997 | -97.92% | -4700.00% | 0.02x | 1.23x | CA$-3.56 Million |
| 1998 | -242.11% | -4600.00% | 0.03x | 1.68x | CA$-3.25 Million |
| 1999 | -12.51% | -859901.04% | 0.00x | 1.05x | CA$-10.33 Million |
| 2000 | -27.20% | -989190.40% | 0.00x | 1.10x | CA$-13.53 Million |
| 2001 | -30.55% | 0.00% | 0.00x | 1.08x | CA$-11.71 Million |
| 2002 | -30.55% | -18454.64% | 0.00x | 1.08x | CA$-11.71 Million |
| 2003 | -105.95% | -4978.98% | 0.02x | 1.20x | CA$-24.34 Million |
| 2004 | -166.31% | -351705.62% | 0.00x | 2.08x | CA$-18.64 Million |
| 2005 | -166.31% | -351705.62% | 0.00x | 2.08x | CA$-18.64 Million |
| 2006 | 0.00% | -271114333.33% | 0.00x | 0.00x | CA$-16.03 Million |
| 2007 | -1267.65% | -9012.99% | 0.01x | 20.35x | CA$-9.09 Million |
| 2008 | 0.00% | -14815.70% | 0.00x | 0.00x | CA$-5.99 Million |
| 2009 | 0.00% | -4789.74% | 0.02x | 0.00x | CA$-7.32 Million |
| 2010 | 0.00% | 4091.86% | 0.06x | 0.00x | CA$5.13 Million |
| 2011 | -596.01% | -8919.72% | 0.04x | 1.65x | CA$-5.24 Million |
| 2012 | 0.00% | -10540.56% | 0.07x | 0.00x | CA$-4.28 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-5.32 Million |
| 2014 | -0.05% | 0.00% | 0.00x | 1.08x | CA$-2.54 Million |
| 2015 | -77.21% | 0.00% | 0.00x | 1.12x | CA$-11.90 Million |
| 2016 | -189.11% | 0.00% | 0.00x | 1.18x | CA$-14.59 Million |
| 2017 | -114.30% | 0.00% | 0.00x | 1.17x | CA$-12.68 Million |
| 2018 | -205.01% | 0.00% | 0.00x | 1.20x | CA$-30.28 Million |
| 2019 | -27.98% | 0.00% | 0.00x | 1.07x | CA$-35.67 Million |
| 2020 | -46.45% | 0.00% | 0.00x | 1.06x | CA$-67.13 Million |
| 2021 | -88.04% | 0.00% | 0.00x | 1.11x | CA$-72.78 Million |
| 2022 | -110.82% | 0.00% | 0.00x | 1.35x | CA$-45.60 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-50.92 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-24.98 Million |
Industry Comparison
This section compares Aptose Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $26,085,261
- Average return on equity (ROE) among peers: -400.36%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aptose Biosciences Inc (APS) | CA$-19.45 Million | -50.53% | N/A | $4.36 Million |
| Appili Therapeutics Inc (APLI) | $-13.40 Million | 0.00% | 0.00x | $1.86 Million |
| Arch Biopartners Inc (ARCH) | $1.06 Million | -79.15% | 0.19x | $20.88 Million |
| Biomind Labs Inc (BMND) | $-1.30 Million | 0.00% | 0.00x | $6.98 Million |
| Cybin Inc (CYBN) | $237.20 Million | -47.70% | 0.09x | $301.37 Million |
| Eupraxia Pharmaceuticals Inc (EPRX) | $1.18 Million | -3177.89% | 21.71x | $393.86 Million |
| Devonian Health Group Inc (GSD) | $14.25 Million | -32.28% | 0.35x | $20.01 Million |
| Helix BioPharma Corp. (HBP) | $-1.39 Million | 0.00% | 0.00x | $116.58 Million |
| Hemostemix Inc (HEM) | $-6.77 Million | 0.00% | 0.00x | $8.18 Million |
| Universal Ibogaine Inc (IBO) | $3.94 Million | -266.20% | 0.60x | $1.13 Million |
About Aptose Biosciences Inc
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloi… Read more